Skip to main content
. 2020 Aug 30;8(2):e001072. doi: 10.1136/jitc-2020-001072

Table 4.

Causes of ALT >100 U/L in HBV-HCC patients on ICI treatment

N (%) HBV DNA ≤100 IU/mL on NUCs (n=10) HBV DNA >100 IU/mL on NUCs (n=11) Patients with HBV without NUCs (n=2)
Tumor progression 9 (90.0) 10 (90.9) 1 (50.0)
HBV reactivation 0 0 1 (50.0)
iRAE hepatitis 1 (10.0) 1 (9.1) 0 (0)

ALT, alanine aminotransferase; HBV, hepatitis B virus; ICI, immune checkpoint inhibitor; iRAE, immunotherapy related adverse event; NUCs, nucleos(t)ide analogs.